New pill helps double survival time for people with advanced pancreatic cancer
A clinical trial has shown that a new daily pill, daraxonrasib, nearly doubles the survival time for patients with advanced pancreatic cancer compared to traditional chemotherapy. The drug also demonstrated fewer severe side effects, offering a potential breakthrough in cancer treatment.
Why it matters
Pancreatic cancer is notoriously difficult to treat, and this drug targets a specific genetic mutation found in the vast majority of these tumors, marking a significant medical advancement.
New pill helps double survival time for people with advanced pancreatic cancer – The Irish News
The article reports on clinical trial results using data and expert quotes without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in